Mr. Jeffrey H. Buchalter, also known as Jeff, BS, MBA, serves as Chief Executive Officer of KBS Healthcare Consulting, Florida. Mr. Buchalter served as the President and Chief Executive Officer at Archimedes Pharma Limited from March 2, 2010 to August 2014. Mr. Buchalter served as an Executive Chairman of Enzon Pharmaceuticals Inc. from September 29, 2004 to July 2009 and its President and Chief Executive Officer from December 2004 to February 22, 2010. He served as the President of ILEX Oncology, Inc. from September 2001 to December 2002 and its Chief Executive Officer from January 1, 2002 to December 2004. He joined ILEX in 2001. He served as the Chief Executive Officer and President of Evivrus, Inc. since December 2004. From 1997 to 2001, he served as Group Vice President and Head of the Worldwide Oncology Franchise at Pharmacia LLC. He held positions at Wyeth, formerly American Home Products and Schering-Plough Corporation. While with Schering Plough Corporation in the late 1980s and early 1990s, he led the launch of INTRON(R) A (interferon alpha-2b), one of the first cytokines to be approved for hairy cell leukemia. From 1993 to 1997, as Group Director for the women's healthcare business of American Home Products, Wyeth Ayerst Laboratories and where he played a key role in the life cycle management of its multibillion-dollar drug PREMARIN(R). He has more than 20 years of pharmaceutical experience and has held key positions at a number of multinational pharmaceutical companies. He has been the Chairman and Non-Executive Director at Inivata Limited since October 2015. He serves as Chairman of KBS Healthcare Consulting, Florida. He served as the Chairman and Director of Evivrus, Inc. since September 2004. He served as the Chairman of the Board of MacroGenics, Inc. since September 26, 2007 and also served as its Director. He has been Non Executive Director of Molecular Partners AG since 2016. He has been a Non-Executive Director of Symphogen A/S since May 10, 2016. He served as a Director at Archimedes Pharma Limited from March 2, 2010 to August 2014. He served as an Independent Director of Topotarget A/S since April 6, 2006. He served as Director of Enzon Pharmaceuticals Inc., from 2004 to February 22, 2010. He served as a Director of ILEX Oncology Inc. from February 2001 to December 2004. He has been a Collaborating Partner in the National Dialogue on Cancer. He acted as the Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States. Among his career honors, he received the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. Mr. Buchalter received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.

 Cancer control and involvement in the oncology pharmaceutical field Onchology   Commercial positioning and development of therapeutics in oncology